Hsa-miR-329-3p inhibits lysine-specific dymethylase 1A (KDM1A), which increases the methylation of Myocyte Enhancer Factor 2D (MEF2D), reducing the expression of PD-L1 and blocking tumor growth, as demonstrated in a xenograft model of HCC [149]. This evidence concerns the gene MEF2D and neoplasm.